Research and Markets (http://www.researchandmarkets.com/research/x88w46/adherens_junction) has announced the addition of the "Adherens Junction Targeting in Oncology Drug Pipeline Update 2015" report to their offering.
Cell-cell adherens junctions, the most common type of intercellular adhesions, are important for maintaining tissue architecture and cell polarity and can limit cell movement and proliferation.
There are today 188 companies plus partners developing 227 targeting adherens junctions drugs in 899 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 128 drugs. Adherens Junction Targeting In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 123 different targets.
All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 120 out of the 121 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information.
All drugs targets are further categorized on in the software application by 29 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Pipeline Breakdown According to Number of Drugs
- Marketed - 20
- Pre-registration - 2
- Phase III - 34
- Phase II - 90
- Phase I - 105
- Preclinical - 112
- No Data - 6
- Suspended - 1
- Ceased - 128
For more information visit http://www.researchandmarkets.com/research/x88w46/adherens_junction
